Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Age- and weight-adjusted rivaroxaban versus standard anticoagulation in children with acute venous thromboembolism
MOH_2017-02-26_000158Phase 3Completed
- Sponsor
- Bayer
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban in venous thromboembolism (VTE) (3 arms), sponsored by Bayer. Primary endpoints: Safety and Efficacy. Started Jun 2014; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on MOH_2017-02-26_000158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-02-26_000158.